These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 21497677

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bisphosphonates: the first 40 years.
    Russell RG.
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [Abstract] [Full Text] [Related]

  • 3. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH.
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
    Ebetino FH, Sun S, Cherian P, Roshandel S, Neighbors JD, Hu E, Dunford JE, Sedghizadeh PP, McKenna CE, Srinivasan V, Boeckman RK, Russell RGG.
    Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
    [Abstract] [Full Text] [Related]

  • 5. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

  • 6. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bisphosphonates: from bench to bedside.
    Russell RG.
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
    Russell RG, Watts NB, Ebetino FH, Rogers MJ.
    Osteoporos Int; 2008 Jun 15; 19(6):733-59. PubMed ID: 18214569
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG, Rogers MJ.
    Bone; 1999 Jul 15; 25(1):97-106. PubMed ID: 10423031
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S, Kamiya S, Ono K.
    Clin Calcium; 2005 May 15; 15(5):819-24. PubMed ID: 15876745
    [Abstract] [Full Text] [Related]

  • 15. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V, Clézardin P.
    Bone; 2011 Feb 15; 48(2):259-66. PubMed ID: 20920623
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New insights into the molecular mechanisms of action of bisphosphonates.
    Rogers MJ.
    Curr Pharm Des; 2003 Feb 15; 9(32):2643-58. PubMed ID: 14529538
    [Abstract] [Full Text] [Related]

  • 19. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
    Rogers MJ, Xiong X, Brown RJ, Watts DJ, Russell RG, Bayless AV, Ebetino FH.
    Mol Pharmacol; 1995 Feb 15; 47(2):398-402. PubMed ID: 7870050
    [Abstract] [Full Text] [Related]

  • 20. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
    Sanders JM, Ghosh S, Chan JM, Meints G, Wang H, Raker AM, Song Y, Colantino A, Burzynska A, Kafarski P, Morita CT, Oldfield E.
    J Med Chem; 2004 Jan 15; 47(2):375-84. PubMed ID: 14711309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.